...
首页> 外文期刊>Thorax: The Journal of the British Thoracic Society >Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.
【24h】

Peak flow variation in childhood asthma: correlation with symptoms, airways obstruction, and hyperresponsiveness during long-term treatment with inhaled corticosteroids. Dutch CNSLD Study Group.

机译:儿童哮喘的峰值流量变化:与长期吸入糖皮质激素治疗期间的症状,气道阻塞和反应过度相关。荷兰CNSLD研究小组。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Guidelines for asthma management focus on treatment with inhaled corticosteroids and on home recording of peak expiratory flow (PEF). The effect of maintenance treatment with inhaled corticosteroids on PEF variation and its relation to other parameters of disease activity were examined in 102 asthmatic children aged 7-14 years. METHODS: During 20 months of treatment with inhaled salbutamol, with or without inhaled budesonide (600 micrograms daily), forced expiratory volume in one second (FEV1), the dose of histamine required to provoke a fall in FEV1 of more than 20% (PD20), the percentage of symptom free days, and PEF variation were assessed bimonthly. PEF variation was computed as the lowest PEF as a percentage of the highest PEF occurring over 14 days, the usual way of expressing PEF variation in asthma self-management plans. For each patient using inhaled corticosteroids within subject correlation coefficients (rho) were computed of PEF variation to the percentage of symptom free days, FEV1, and PD20. RESULTS: PEF variation decreased significantly during the first two months of treatment with inhaled corticosteroids and then remained stable. The same pattern was observed for symptoms and FEV1. In contrast, PD20 histamine continued to improve throughout the whole follow up period. In individual patients predominantly positive associations of PEF variation with symptoms, FEV1, and PD20 were found, but the ranges of these associations were wide. CONCLUSIONS: During treatment with inhaled corticosteroids the changes in PEF variation over time show poor concordance with changes in other parameters of asthma severity. When only PEF is monitored, clinically relevant deteriorations in symptoms, FEV1, or PD20 may be missed. This suggests that home recording of PEF alone may not be sufficient to monitor asthma severity reliably in children.
机译:背景:哮喘管理指南的重点在于吸入皮质类固醇的治疗以及峰值呼气流量(PEF)的家庭记录。在102名7-14岁的哮喘儿童中,研究了吸入糖皮质激素维持治疗对PEF变化的影响及其与疾病活动其他参数的关系。方法:在吸入沙丁胺醇,有或没有吸入布地奈德(每天600微克),用力呼气量在一秒钟内(FEV1)进行治疗的20个月中,引起FEV1下降所需的组胺剂量超过20%(PD20 ),每两个月评估一次无症状天数百分比和PEF变化。 PEF变异计算为在14天中发生的最低PEF占最高PEF的百分比,这是哮喘自我管理计划中表达PEF变异的常用方法。对于每位使用吸入糖皮质激素的患者,计算出受试者的PEF变化与无症状天数,FEV1和PD20的百分比之间的相关系数(rho)。结果:吸入皮质类固醇治疗的前两个月,PEF变化显着降低,然后保持稳定。症状和FEV1观察到相同的模式。相反,PD20组胺在整个随访期间持续改善。在个别患者中,发现PEF变异与症状,FEV1和PD20呈正相关,但是这些关联的范围很广。结论:在吸入皮质类固醇治疗期间,PEF随时间的变化显示与哮喘严重程度其他参数的变化不一致。仅监视PEF时,可能会漏掉临床上与症状有关的恶化,FEV1或PD20。这表明仅在家中记录PEF可能不足以可靠地监测儿童的哮喘严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号